Le Lézard
Classified in: Health, Business
Subjects: PER, WOM, STP

Prestige Health Choice Pharmacy Director, Holly Moreau, Pharm.D., appointed to the Florida Medicaid Pharmaceutical and Therapeutics Committee by Florida Governor Rick Scott


PALM BEACH GARDENS, Fla., Nov. 9, 2017 /PRNewswire/ -- Prestige Health Choice, a Medicaid managed care plan serving 55 of Florida's 67 counties and a joint venture between AmeriHealth Caritas and Florida Blue, announced today that Florida Governor Rick Scott has appointed Dr. Moreau to Florida's Medicaid Pharmaceutical and Therapeutics (P&T) Committee. Dr. Moreau's term runs from October 17, 2017 to June 30, 2021.

Holly Moreau, Pharm.D., Prestige Health Choice Pharmacy Director

Dr. Moreau is one of 11 committee members. The P&T Committee makes recommendations to the Agency for Health Care Administration (AHCA) on additions to and deletions from the Florida Medicaid's Preferred drug list (PDL) based on the drugs' clinical efficacy, safety and cost effectiveness.  

Dr. Moreau has more than 15 years of formulary management experience. In her current role at Prestige Health Choice, Dr. Moreau develops programs designed to increase access to appropriate medications as a means to improve overall health care outcomes and close care gaps.

"It's an honor to be chosen for this position," Dr. Moreau said. "The Medicaid Pharmaceutical and Therapeutics Committee plays a critical role in helping Floridians most in need access safe and cost-effective medications and drug treatments. I look forward to applying my experience at Prestige Health Choice to help AHCA build a PDL that meets the needs of Florida's Medicaid recipients while making the best use of tax dollars."

"We are extremely pleased and proud of Dr. Moreau's appointment and her commitment to service to AHCA and the Florida Medicaid program," said Prestige Health Choice's Chief Medical Officer  Sandra Schwemmer, D.O., FACOEP-D, FACEP, FAAOE, LHRM. "PDL management is important in an integrated patient care process that  enables health care professionals to collectively promote clinically sound, cost-effective medication therapy and positive therapeutic outcomes ."

About Prestige Health Choice
Prestige Health Choice is a Medicaid managed care plan serving members in 55 of Florida's 67 counties.  Prestige's strength is founded on its longstanding provider partnerships, particularly with federally qualified health centers and other safety-net providers. A Florida-based company, Prestige is owned and operated by Florida True Health, a joint venture of AmeriHealth Caritas and Florida Blue. For more information, visit www.prestigehealthchoice.com.

About AmeriHealth Caritas 
AmeriHealth Caritas is part of the Independence Health Group in partnership with Blue Cross Blue Shield of Michigan. AmeriHealth Caritas is one of the nation's leaders in health care solutions for those most in need. Operating in 17 states and the District of Columbia, AmeriHealth Caritas serves more than 5.7 million Medicaid, Medicare and Children's Health Insurance Program (CHIP) members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, behavioral health services, and other administrative services. Headquartered in Philadelphia, AmeriHealth Caritas is a mission-driven organization with more than 30 years of experience serving low-income and chronically ill populations. For more information, visit www.amerihealthcaritas.com.

About Florida Blue
Florida Blue is a leader in Florida's health care industry. Its  mission is to help people and communities achieve better health.  Florida Blue has 5 million health care members, with nearly 18 million people in 12 states served through its affiliated companies. Headquartered in Jacksonville, Fla., it is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. For more information, visit www.FloridaBlue.com.

 

SOURCE Prestige Health Choice


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: